D-049
N-Desmethylclobazam solution
100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C15H11ClN2O2
CAS Number:
Molecular Weight:
286.71
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Recommended Products
grade
certified reference material
Quality Level
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
100 μg/mL in acetonitrile
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
SMILES string
O=C(C1)N(C2=CC=CC=C2)C3=C(C=CC(Cl)=C3)NC1=O
InChI
1S/C15H11ClN2O2/c16-10-6-7-12-13(8-10)18(11-4-2-1-3-5-11)15(20)9-14(19)17-12/h1-8H,9H2,(H,17,19)
InChI key
RRTVVRIFVKKTJK-UHFFFAOYSA-N
General description
A Certified Solution Standard for use in LC or GC applications from forensic and forensic toxicology analysis to urine drug testing. N-Desmethylclobazam, found in urine, serum, and plasma, is the pharmacologically active, major metabolite of clobazam.
Application
- Impact on bioavailability in epilepsy treatment: A study discussed the implications of N-Desmethylclobazam on drug to drug interactions and neuropsychological impact when used as add-on therapy in drug-resistant epilepsies, highlighting its role in enhancing therapeutic bioavailability (Pietrafusa et al., 2023).
- Research on pharmacokinetic variability: Research explored the pharmacokinetic variability of N-Desmethylclobazam, emphasizing its influence by age, drug interactions, and biochemical markers of toxicity in patients with epilepsy, contributing to a deeper understanding of its pharmacological properties (Heger et al., 2024).
- Evaluation of drug-drug interactions: A comprehensive analysis investigated potential drug-drug interactions between N-Desmethylclobazam and anti-seizure medications, providing insights into its safe and effective use in clinical settings (Gaston et al., 2023).
- Synergistic effects in epilepsy management: A multicenter study on the cenobamate-clobazam interaction revealed both pharmacokinetic interactions and evidence of synergy, underscoring N-Desmethylclobazam′s potential to enhance treatment outcomes in epilepsy (Osborn and Abou-Khalil, 2023).
- Analysis of metabolites in forensic science: Research on the measurement of benzodiazepine receptor agonists′ metabolites, including N-Desmethylclobazam, outlined its detection and concentration levels in urine, offering applications in forensic toxicology (Volkova et al., 2023).
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
related product
Product No.
Description
Pricing
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2
Storage Class Code
3 - Flammable liquids
WGK
WGK 2
Flash Point(F)
35.6 °F - closed cup
Flash Point(C)
2 °C - closed cup
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
T Pullar et al.
British journal of clinical pharmacology, 24(6), 793-797 (1987-12-01)
1. The single dose pharmacokinetics of N-desmethylclobazam (NDMC) and clobazam were studied in eight healthy male volunteers. 2. Steady-state pharmacokinetic data are described from four healthy male volunteers and eight epileptic patients taking NDMC. 3. A single 30 mg dose
A Guberman et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 17(3), 311-316 (1990-08-01)
Clobazam, a novel benzodiazepine, was used as an add-on agent in 47 adult patients with intractable epilepsy and a variety of seizure types. A greater than 75% reduction in seizure frequency was observed in 42% (18) of the patients and
A H Bardy et al.
Brain & development, 13(3), 174-179 (1991-05-01)
Clobazam was added to the previous antiepileptic drug therapy of 90 children suffering from drug resistant epilepsy. Ten patients became seizure free, although four of these later developed tolerance. Thirty-three patients experienced a decrease in seizure frequency, and 24 of
Mohammadreza Rouini et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 823(2), 167-171 (2005-07-12)
A rapid and specific HPLC method has been developed and validated for simultaneous determination of clobazam, the anticonvulsant agent, and its major metabolite in human plasma. The sample preparation was a liquid-liquid extraction with tuloene yielding almost near 100% recoveries
R Herráez-Hernández et al.
Journal of pharmaceutical and biomedical analysis, 14(8-10), 1077-1087 (1996-06-01)
An on-line dialysis-solid-phase extraction-gas chromatographic (GC) approach has been developed for the determination of drugs in plasma, using some benzodiazepines as model compounds. Clean-up is based on performing the dialysis of 100 microliters samples for 7 min using water as
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service